Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study
Journal of Oncology · 15.04.2023 · 2023 · 1-8
DOI: 10.1155/2023/6353047 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Oncology, erschienen am 15.04.2023. Verfasst von Kang Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Basic Research Program of China.
Abstract (Originalsprache)
Aim
Locoregional treatment, such as TACE, in combination with immunotherapy may elicit a synergistic anticancer effect. However, TACE combined with atezolizumab plus bevacizumab (atezo/bev) has not been investigated for patients with intermediate stage (BCLC B) HCC beyond the up-to-seven criteria. This study aims to evaluate the efficacy and safety of this treatment strategy in intermediate-stage HCC patients with large or multinodular tumors exceeding the up-to-seven criteria.
Methods
This multicenter retrospective study included patients with intermediate stage (BCLC B) HCC beyond the up-to-seven criteria treated with TACE combined with atezo/bev from five centers in China from March to September 2021. The outcomes of this study included the objective response rate (ORR), overall survival (OS), and progression-free survival (PFS). Treatment-related adverse events (TRAEs) were analyzed to assess safety.
Results
A total of 21 patients were enrolled in this study, with a median follow-up duration of 11.7 months. According to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, the best ORR was 42.9% and the DCR was 100%. According to modified RECIST (mRECIST), the best ORR and DCR were 61.9% and 100%, respectively. The median PFS and OS were not reached. The most common TRAEs at all levels were fever (71.4%), and the most common grade 3/4 TRAE was hypertension (14.3%).
Conclusions
TACE combined with atezo/bev showed encouraging efficacy and an acceptable safety profile, making it a promising treatment option for patients with BCLC B HCC beyond the up-to-seven criteria, which will be further investigated in a prospective single-arm trial.
Autor:innen und Institutionen
- Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
- Hepato-Pancreato-Biliary Center, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China.
- Department of Liver Surgery, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
- Department of Hepatobiliary Surgery, Qilu Hospital of Shandong University, Jinan, China.
- Department of Hepatobiliary Surgery, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, China.
ORCID-Profile: Hongfei Zhu, Yanjun Xiang, Tao Li, Shuqun Cheng
Förderung
- National Basic Research Program of China
Zitieren
APA
Wang, K., Zhu, H., Yu, H., Cheng, Y., Xiang, Y., Cheng, Z., Li, Y., Li, T., Wang, D., Zhu, Z., & Cheng, S. (2023). Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of Oncology, 2023, 1-8. https://doi.org/10.1155/2023/6353047
Vancouver
Wang K, Zhu H, Yu H, Cheng Y, Xiang Y, Cheng Z, et al. Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study. Journal of Oncology. 2023;2023:1-8. doi:10.1155/2023/6353047
BibTeX
@article{Wang2023,
author = {Wang, Kang and Zhu, Hongfei and Yu, Hongming and Cheng, Yuqiang and Xiang, Yanjun and Cheng, Zhangjun and Li, Yang and Li, Tao and Wang, Dongxu and Zhu, Zhenyu and Cheng, Shuqun},
title = {Early Experience of TACE Combined with Atezolizumab plus Bevacizumab for Patients with Intermediate-Stage Hepatocellular Carcinoma beyond Up-to-Seven Criteria: A Multicenter, Single-Arm Study},
journal = {Journal of Oncology},
year = {2023},
volume = {2023},
pages = {1--8},
doi = {10.1155/2023/6353047}
}
EUVIMED